Literature DB >> 4183680

Breakdown products of C 3 in human synovial fluids.

N J Zvaifler.   

Abstract

Activation of the complement sequence results in conversion of the third component of complement (C'3) to an inactive product (C'3i) and the elaboration of additional fragments of smaller molecular weights and faster electrophoretic mobilities. Immunoelectrophoretic analysis of fresh synovial fluids with an anti-human C'3 antiserum disclosed in some a variable degree of conversion of C'3 to C'3i, but a more striking finding was an additional line in the alpha-globulin region. This faster migrating protein gave a reaction of partial identity with C'3/C'3i. With this antiserum a similar pattern developed when fresh human serum was incubated with immune complexes, or aggregated gamma-globulin. The same breakdown product of C'3 was obtained by treatment of fresh human serum with Zymosan, ammonium, hydrazine, agar, or dextran. Heating serum at 56 degrees C for 1 hr destroys the breakdown product; aging of serum produces it. Breakdown products of C'3 were looked for in 49 synovial fluids from patients with a variety of joint diseases. A significant correlation was found between the demonstration of the fast migrating breakdown product of C'3 and the diagnosis of rheumatoid arthritis and the presence of rheumatoid factor. A similar immunoelectrophoretic pattern was not found in the serum of any of the patients studied. When human gamma-globulin, which has been reduced and alkylated, is heat aggregated it loses the ability to fix human complement but still reacts with rheumatoid factor. Addition of reduced, aggregated gamma-globulin to fresh normal human serum produced no conversion of C'3, but when incubated with serum containing a high titer of rheumatoid factor, there was conversion of C'3 and the appearance of a breakdown product. Quantitative complement fixation studies with fresh serum from normal subjects and patients with rheumatoid arthritis disclosed complement fixation by reduced, aggregated gamma-globulin. The per cent of complement fixation was proportional to the titer of rheumatoid factor present in the test serum. These findings were interpreted as showing that rheumatoid factor can fix complement.The possibility is discussed that the presence of breakdown products of C'3 in the synovial effusions of most patients with seropositive rheumatoid arthritis and the ability of rheumatoid factor to fix complement are related phenomena.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4183680      PMCID: PMC322380          DOI: 10.1172/JCI106119

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Immunofluorescent localization of the third and the fourth component of complement in synovial tissue from patients with rheumatoid arthritis.

Authors:  W S Rodman; R C Williams; P J Bilka; H J Müller-Eberhard
Journal:  J Lab Clin Med       Date:  1967-01

2.  Altered complement component C3A (beta-1C--beta-1A) in patients with glomerulonephritis.

Authors:  J F Soothill
Journal:  Clin Exp Immunol       Date:  1967-01       Impact factor: 4.330

3.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

4.  Relation of intracytoplasmic inclusions in joint fluid leukocytes to anti-gamma-G globulins.

Authors:  J H Vaughan; R J Jacox; P Noell
Journal:  Arthritis Rheum       Date:  1968-04

5.  Antinuclear factors in synovia. Possible participants in the rheumatoid inclusion body.

Authors:  E V Barnett; J Bienenstock; K J Bloch
Journal:  JAMA       Date:  1966-10-10       Impact factor: 56.272

6.  The clinical significance of deoxyribonucleic acid particles in synovial fluid.

Authors:  T J Pekin; T I Malinin; N J Zvaifler
Journal:  Ann Intern Med       Date:  1966-12       Impact factor: 25.391

7.  Evidence for in vivo breakdown of beta-10-globulin in hypocomplementemic glomerulonephritis.

Authors:  C D West; S Winter; J Forristal; J M McConville; N C Davis
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

8.  Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.

Authors:  C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

9.  A plasmin-split fragment of C'3 as a new chemotactic factor.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  33 in total

1.  Studies of the action of some anti-inflammatory drugs on complement mediated immune haemolysis.

Authors:  K Whaley; D J Sloane
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

2.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

3.  Complement lesions in cell membranes from joint effusions of various types of arthritis.

Authors:  R R Dourmashkin; S Patterson
Journal:  Inflammation       Date:  1976-03       Impact factor: 4.092

4.  Concentrations of glycosaminoglycans in synovial fluids and their relation with immunological and inflammatory mediators in rheumatoid arthritis.

Authors:  A Bensouyad; A P Hollander; B Dularay; A E Bedwell; R A Cooper; C W Hutton; P A Dieppe; C J Elson
Journal:  Ann Rheum Dis       Date:  1990-05       Impact factor: 19.103

Review 5.  Rheumatoid arthritis: review of searches for an infectious cause. Part II.

Authors:  E Wilkes; E S Meek
Journal:  Infection       Date:  1979       Impact factor: 3.553

6.  Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the disease.

Authors:  R H Zubler; U Nydegger; L H Perrin; K Fehr; J McCormick; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

7.  Complement activating properties of complexes containing rheumatoid factor in synovial fluids and sera from patients with rheumatoid arthritis.

Authors:  C J Elson; S D Carter; B J Cottrell; D G Scott; P A Bacon; T B Wallington
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

8.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

9.  Plasma and synovial fluid levels of granulocytal elastase-alpha-1-protease inhibitor complex in patients with rheumatoid arthritis.

Authors:  K Kuramitsu; A Yoshida
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

10.  Enhancement of human lymphocyte transformation by aggregated human gamma globulin.

Authors:  T D Kinsella
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.